PHARMAPACK EXHIBITORS AT PHARMAPACK EUROPE 2024 Bormioli Pharma Booth B78-B79 Bormioli Pharma presents its wide range of quality, cutting-edge products and services at Pharmapack Europe 2024 Bormioli Pharma, global leader in pharmaceutical packaging and medical devices, will make its mark at Pharmapack Europe in Paris (Booths B78-B79) on January 24-25, presenting its wide portfolio line-up, composed by a complete com-th th mercial offering of primary packaging in glass and plastic and of a scientific counsel approach, confirming its position as a quality player throughout the value chain. Bormioli Pharma’s portfolios refer to the different segments’ specific needs: high-value prescription drugs (forTherapy), daily medications and OTCs (forHealth), nutraceuticals and food supplements (forLife). High-quality containers, includingType I molded and tubing glass vials, along with closures and accessories, are part of Bormioli Pharma’s forTherapy Portfolio. In this context, the Group enhances its value by offering additional services streamlining operational efficiency, such as theready-to-sterilize and theready-to-use options. ForHealth portfolio offers diversedaily medication and OTC drug solutions, from primary packaging to accessories and child-proof closures, featuring barrier additives positively impacting on emissions and sustainability. Simultaneously, ForLifeportfolioresponds to the growing demand for nutraceuticals and supplements with itsinnova- tive dual chamber systems, as well aspresenting a new tethered tamper-evident cap, fighting the dispersion of plastic. With a commitment to its mission of "Making health a positive practice, accessible to everyone, kind to the planet", Bor- mioli Pharma’s EcoPositive range operates to create a range of sustainable approaches aligned with product portfolios. At Pharmapack 2024, new solutions will be showcased, includingmono-dose caps, rPP tear-offs and external child-proof shells. Finally, on 25 January (10.50-11.20am), Bormioli Pharma will host a Learning Lab, crafted to share details on Invents,th the new Bormioli Pharma’s innovation platform, showing collaboration case studies that allowed an acceleration of therapies go-to-market.